All In MedTech

Device Trial Radar · NCT00814840

Efficiency Study of Triple-Site Cardiac Resynchronization in Patients With Heart Failure

Triple-Site Versus Standard Cardiac Resynchronization Therapy (TRUST CRT) Randomized Trial

Last checked: Nov 19, 2026Latest source record: Apr 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Feb 2008

Primary completion

Jul 2010

Study completion Jan 2015

Sponsor

Lead sponsor
Silesian Centre for Heart DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 25, 2008

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficiency of permanent biventricular pacing using three ventricular leads in terms of reduction in adverse cardiac events rates, improvement in cardiac capacity and patients' functional status in subjects with congestive heart failure and a physiologic (sinus) rhythm.

Conditions

  • Congestive Heart Failure
  • Heart Disease

Interventions

  • Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leadsDevice

    Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)

  • Triple-site cardiac resynchronizationDevice

    Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined end-point of alive status, freedom from hospitalization for HF or heart transplantation, relative ≥10% increase in LV ejection fraction, ≥10% in VO2max and ≥10% in 6MWD.Time frame: six months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Department of Cardiology, Silesian Medical University, Silesian Center for Heart Diseases

    Zabrze, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.